The patent comes months after Immunic Therapeutics announced CALLIPER study results, which tested vidofludimus calcium in progressive MS.

July 22, 2025 – A promising new drug could soon transform treatment for one of the most challenging types of multiple sclerosis – and with FDA approval expected in the coming months, it's being hailed ...

In this article, ACRO explores multiple sclerosis—a silent battle unfolding within the central nervous system.

In a new study, researchers found that increased expression of gene PRDM1-S triggers loss of immune regulation in autoimmune conditions like multiple sclerosis (MS). The findings could pave the way ...

A new FDA target action date of 28 December could bring tolebrutinib’s tumultuous development period to an end.

Biologic drugs are typically given as infusions that can take an hour or longer. The FDA has approved injectable versions of two biologic Roche drugs, one for multiple sclerosis and the other for ...

Multiple sclerosis (MS) is recognized as one of the most prevalent neurological diseases among young adults, with symptoms typically emerging between ages 20 to 40 years. The condition is ...

(Reuters) -Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive surprise succeeded in a ...

Sanofi has agreed to pay $315 million to settle claims that it slowed the development of a multiple sclerosis drug to avoid paying investors after the company acquired Genzyme Corp. The lawsuit, filed ...

Quantum BioPharma Ltd. announced the completion of dosing in 90-day oral toxicity and toxicokinetic studies for its drug Lucid-21-302 (Lucid-MS), aimed at treating Multiple Sclerosis (MS). This ...

Tiziana Life Sciences (NASDAQ:TLSA) recently announced that it submitted its IND of fully human anti-CD3 monoclonal antibody foralumab to begin a phase 2 study for the treatment of patients with ...